I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...
PARP inhibitors (PARPi) leverage synthetic lethality in BRCA-deficient cancers, yet intrinsic resistance limits therapeutic benefit. Through functional proteomics, this study uncovers that PARPi ...
Research shows that the breast cancer gene 1 (BRCA1) not only pushes accurate DNA repair to guard against cancer but promotes subsequent activity in tumor suppression. A new study led by The ...
A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results